The present disclosure provides a method for extracting alpha-ketoglutarate and pyruvate simultaneously from microbial fermentation broth or enzyme transformation solution, which is related to the technical field of biological separation and extraction. The method comprises the following steps: centrifuging the microbial fermentation broth or enzymatic conversion solution containing -KG and PA to remove the cells and other visible solids; removing the macromolecular impurities by ultrafiltration; evaporating and concentrating under reduced pressure conditions; extracting with the water-insoluble extraction after acidification; separating crude crystals of -KG and crude liquid of PA by evaporation crystallization method (if concentration of PA is great higher than that of -KG, crystallization separation should be conducted after distilling partial pure pyruvate); washing the crude crystal of -KG with water-insoluble organic solvent as ethyl acetate or butyl acetate, drying and crushing to obtain qualified -KG; distilling to gain qualified PA product applying high vacuum distillation (or molecular distillation).

The present invention relates to catalytic conversion of ketoacids, including methods for increasing the molecular weight of ketoacids. The method can include providing in a reactor a raw material having at least one ketoacid. The raw material is then subjected to one or more CC-coupling reaction(s) in the presence of an ion exchange resin catalyst to produce at least one ketocid dimer. The method can include providing in a reactor a feedstock having the at least one ketoacid dimer and subjecting the feedstock to one or more CC-coupling reaction(s) at a temperature of at least 200 C.

The present invention relates to catalytic conversion of ketoacids, including methods for increasing the molecular weight of ketoacids. The method can include providing in a reactor a raw material having at least one ketoacid. The raw material is then subjected to one or more CC-coupling reaction(s) in the presence of an ion exchange resin catalyst to produce at least one ketocid dimer. The method can include providing in a reactor a feedstock having the at least one ketoacid dimer and subjecting the feedstock to one or more CC-coupling reaction(s) at a temperature of at least 200 C.

Provided is a silver ink including, as a major component, a silver malonate precursor represented by Formula 1 or Formula 2.

Provided is a silver ink including, as a major component, a silver malonate precursor represented by Formula 1 or Formula 2.

A lithographic method includes forming a photoresist layer on a target layer, forming a photo-decomposable base (PDB) layer on the photo resist layer, performing an exposure operation using a mask, and performing a negative development treatment to form a patterned photoresist layer on the target layer. In some cases, the photo-decomposable base layer includes a self-generating top coating photo-decomposable base (TC-PDB) layer. The method can also include forming a top surface water-resistant coating in separate coating process. In some embodiments, a top surface water-resistant coating is self-generated during a photoresist coating process.

A lithographic method includes forming a photoresist layer on a target layer, forming a photo-decomposable base (PDB) layer on the photo resist layer, performing an exposure operation using a mask, and performing a negative development treatment to form a patterned photoresist layer on the target layer. In some cases, the photo-decomposable base layer includes a self-generating top coating photo-decomposable base (TC-PDB) layer. The method can also include forming a top surface water-resistant coating in separate coating process. In some embodiments, a top surface water-resistant coating is self-generated during a photoresist coating process.

Salts of the 5-HT2C-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and dosage forms comprising them that are useful for, inter alia, weight management.

Salts of the 5-HT2C-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and dosage forms comprising them that are useful for, inter alia, weight management.

A process for preparing a reverse osmosis membrane that includes: (A) providing a polyamine, a polyfunctional acid halide, and a flux increasing additive having the formula Z.sup.+B.sup., where Z.sup.+ is an easily dissociable cation and B.sup. is a beta-diketonate; (B) combining the polyamine, polyfunctional acid halide, and flux increasing additive on the surface of a porous support membrane; and (C) interfacially polymerizing the polyamine and the polyfunctional acid halide, and flux increasing additive on the surface of the porous support membrane to form a reverse osmosis membrane comprising (i) the porous support membrane and (ii) a discrimination layer comprising a polyamide. The reverse osmosis membrane is characterized by a flux that is greater than the flux of the same membrane prepared in the absence of the flux increasing additive.